Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Action: Physiological Effects

Perifosine Mechanisms of Action in Leishmania Species

Atteneri López-Arencibia, Carmen Martín-Navarro, Ines Sifaoui, María Reyes-Batlle, Carolina Wagner, Jacob Lorenzo-Morales, Sutherland K. Maciver, José E. Piñero
Atteneri López-Arencibia
aCentre for Integrative Physiology, Biomedical Sciences, Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom
bUniversity Institute of Tropical Diseases and Public Health of the Canary Islands, University of La Laguna, Canary Islands, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmen Martín-Navarro
bUniversity Institute of Tropical Diseases and Public Health of the Canary Islands, University of La Laguna, Canary Islands, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ines Sifaoui
cLaboratoire Matériaux-Molécules et Applications, University of Carthage, La Marsa, Tunisia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María Reyes-Batlle
bUniversity Institute of Tropical Diseases and Public Health of the Canary Islands, University of La Laguna, Canary Islands, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina Wagner
bUniversity Institute of Tropical Diseases and Public Health of the Canary Islands, University of La Laguna, Canary Islands, Spain
dCátedra de Parasitología, Escuela de Bioanálisis, Universidad Central de Venezuela, Venezuela
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacob Lorenzo-Morales
bUniversity Institute of Tropical Diseases and Public Health of the Canary Islands, University of La Laguna, Canary Islands, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sutherland K. Maciver
aCentre for Integrative Physiology, Biomedical Sciences, Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
José E. Piñero
bUniversity Institute of Tropical Diseases and Public Health of the Canary Islands, University of La Laguna, Canary Islands, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.02127-16
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Here the mechanism by which perifosine induced cell death in Leishmania donovani and Leishmania amazonensis is described. The drug reduced Leishmania mitochondrial membrane potential and decreased cellular ATP levels while increasing phosphatidylserine externalization. Perifosine did not increase membrane permeabilization. We also found that the drug inhibited the phosphorylation of Akt in the parasites. These results highlight the potential use of perifosine as an alternative to miltefosine against Leishmania.

TEXT

Leishmania species are obligate intracellular parasites that are transmitted to the mammalian host by the bites of infected sand flies. Cutaneous leishmaniasis (CL), the most common form of leishmaniasis, is a group of diseases with a varied spectrum of clinical manifestations that range from small cutaneous nodules to wide mucosal tissue destruction. Visceral leishmaniasis (VL), characterized by prolonged fever and splenomegaly, is the most severe form, and it is often fatal if untreated (1).

The World Health Organization (WHO) estimates that 1.5 million cases of CL and 500,000 cases of VL occur every year in 82 countries. CL is endemic in more than 70 countries worldwide, and 90% of cases occur in Afghanistan, Algeria, Brazil, Pakistan, Peru, Saudi Arabia, and Syria. VL presents in 65 countries, and the majority (90%) of these cases occur in five countries, Bangladesh, India, Nepal, Sudan, and Brazil. Estimates indicate that there are approximately 350 million people at risk for acquiring leishmaniasis, with 12 million currently infected worldwide (1).

The current available leishmanicidal treatments include pentavalent antimonials, amphotericin B, miltefosine, paromomycin, and pentamidine. These drugs can be administered alone or in combination with each other. However, these drugs are normally highly toxic, even at low doses. Furthermore, most of these treatments require several days of hospitalization because of their intravenous or parenteral manner of administration. The appearance of strains resistant to these active compounds presents a major problem for the current therapeutic measures against these parasites (2). Moreover, since there is no immediate prospect of a vaccine for leishmaniasis (3), there is an urgent need to develop novel leishmanicidal agents.

Several typical markers of mammalian apoptosis have been found in Leishmania, suggesting the existence of an apoptosis-like death in these organisms. The markers include cell shrinkage, nuclear chromatin condensation, DNA fragmentation, membrane blebbing, mitochondrial transmembrane potential loss, and phosphatidylserine exposure (4).

Perifosine was purchased from Cayman Chemical, and miltefosine, used as reference drug, was provided by Æterna Zentaris. In this study, strains of Leishmania amazonensis (MHOM/BR/77/LTB0016) and Leishmania donovani (MHOM/IN/90/GE1F8R) were used. The murine macrophage J774A.1 (ATCC TIB-67) cell line was also used to evaluate host cell toxicity.

For the activity assays against the promastigote stage of Leishmania spp., a colorimetric assay based on alamarBlue reagent (Invitrogen, Life Technologies) was used as previously described (5).

Activity assays against intracellular amastigotes were performed as previously described with minor modifications (6). For the toxicity assay, an LDH cytotoxicity detection kit (Roche Applied Science) was used (7). The results against the promastigote and intracellular amastigote stages are shown in Table 1, as are the cytotoxicities and selectivity indexes (SIs). The 50% inhibitory concentrations (IC50s) are consistent with data obtained in previous studies (5, 8). A study by Glaser et al. (9) showed similar cytotoxicity data for miltefosine.

View this table:
  • View inline
  • View popup
TABLE 1

Leishmanicidal activities, cytotoxicities, and SIs of the tested alkylphospholipids

For measuring changes in the mitochondrial membrane potential (ΔΨm) of L. amazonensis and L. donovani, the JC-1 mitochondrial membrane potential assay kit (Cayman Chemical) was used. The ratio of the reading at 595 nm to the reading at 535 nm was considered the relative ΔΨm value (10). The two molecules induced decreases in the ΔΨm in both parasitic strains; the decrease was greater in the case of L. amazonensis (Fig. 1).

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

(A) ATP levels of L. amazonensis and L. donovani after 24 h of incubation with the IC90s of perifosine and miltefosine. (B) Changes in the mitochondrial membrane potential (ΔΨm) of L. amazonensis and L. donovani after 24 h of incubation with the IC90 of perifosine and miltefosine. Error bars represent the standard deviation (SD). Each data point indicates the mean of three measurements. (C) Images of L. amazonensis incubated with JC-1 dye after 24 h of treatment with the IC90 of perifosine; images of negative controls of parasites without treatment are shown on the upper left and upper right.

ATP levels were measured using the Cell Titer-Glo luminescent cell viability assay (Promega). This assay proved the strong effects of miltefosine and perifosine in decreasing ATP levels (Fig. 1). The apoptosis-like process in Leishmania spp. requires ATP to carry out all the involved procedures; however, it seems that ATP levels are maintained by either glycolysis and/or minimal mitochondrial activity to support the parasite metabolism until the conclusion of the apoptosis-like process (11).

The Tali apoptosis kit (annexin V Alexa Fluor 488 and propidium iodide) (Life Technologies) double-staining assay was performed according to manufacturer instructions using a Tali image-based cytometer. Figure 2 shows all the obtained results. Moreover, the differences in the amounts of annexin V observed between the two strains of Leishmania (amounts were greater in L. amazonensis) might have been due to differences in the amount of polysaccharides (PSs) present in the membrane of the parasites (12).

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

(A) Results of phosphatidylserine exposure after 48 h of incubation with the IC90s of perifosine and miltefosine. Error bars represent the standard deviation (SD). Each data point indicates the mean of three measurements. Images of L. amazonensis (B) and L. donovani (C) captured using a Tali image-based cytometer.

Plasma membrane permeability was measured using SYTOX Green (Molecular Probes). The results confirmed that the plasma membrane integrity was not altered in the treated parasites, at least not in the first 6 h of treatment (Fig. 3). This provided us with important data with which to distinguish between apoptosis and necrosis, considering the rupture of the plasma membrane, which is a morphological feature of necrosis (13). Also, this assay might indicate that the target of these molecules is not likely to be primarily the plasma membrane of the parasites (14).

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

(A) Plasma membrane permeability assay results for L. amazonensis and L. donovani. Triton X-100 was added to obtain 100% permeabilized cells, and amphotericin B (10 μM) was used as positive control. (B) Changes in the relative expression of phosphorylated kinases on L. donovani after 24 h of incubation with the IC90 of perifosine. Error bars represent the standard deviation (SD). Each data point indicates the mean of three measurements.

The Human Phospho-Kinase Array 1 proteome profiler (R&D Systems) was used for the phosphorylation analysis of different kinases during the promastigote stage and was developed by chemiluminescence using ChemiDoc XRS+ image capture (Bio-Rad). The Q-View software (Quansys Biosciences) was used to measure pixel density. All statistical analyses were performed with Sigma Plot 12.0 (Systat Software). After incubation of L. donovani with perifosine, one protein presented a difference in its relative expression, a decrease in the phosphorylation levels of Akt (phosphorylation of S473) necessary for its activation (Fig. 3). Miltefosine is an inhibitor of Akt in Leishmania (15), and perifosine also inhibits Akt protein in human cancer cells (16). These facts lead us to believe that perifosine has the same Akt-inhibiting capacity in Leishmania, which leads to the induction of an apoptosis-like cell death that is known to occur with miltefosine in L. amazonensis (17) and L. donovani (18).

Previous results obtained in our laboratory on alkylphospholipids showed that perifosine was superior to miltefosine and edelfosine in killing Leishmania promastigotes in vitro (5), and we also showed that perifosine was superior to other alkylphospholipids in an in vivo mouse model (19). We now conclude that perifosine induces an apoptosis-like process in L. amazonensis and L. donovani at very low doses, which makes perifosine a promising candidate for further study and possible therapeutic use in humans.

ACKNOWLEDGMENTS

This work was supported by the RICET grants (project RD12/0018/0012 of the programme of Redes Temáticas de Investigación Cooperativa, FIS), Spanish Ministry of Health, Madrid, Spain; PI13/00490 “Protozoosis Emergentes por Amebas de Vida Libre: Aislamiento, Caracterización, Nuevas Aproximaciones Terapéuticas y Traslación Clínica de los Resultados” from the Instituto de Salud Carlos III; and Project BIO24 “Principios activos inductores de apoptosis en la quimioterapia de tripanosomosis y leishmaniosis” (project 2016_25) from Obra Social La Caixa-Fundación CajaCanarias. A.L.-A. was funded by a grant from “Fundación Canaria Doctor Manuel Morales” and the Agustín de Betancourt Programme, and J.L.-M. was supported by the Ramón y Cajal Subprogramme from the Spanish Ministry of Science and Innovation (grant RYC-2011-08863).

FOOTNOTES

    • Received 4 October 2016.
    • Returned for modification 17 November 2016.
    • Accepted 8 January 2017.
    • Accepted manuscript posted online 17 January 2017.
  • Copyright © 2017 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    World Health Organization. 2016: Leishmaniasis: background information. http://www.who.int/leishmaniasis/en/.
  2. 2.↵
    1. Croft SL,
    2. Sundar S,
    3. Fairlamb AH
    . 2006. Drug resistance in leishmaniasis. Clin Microbiol Rev19:111–126. doi:10.1128/CMR.19.1.111-126.2006.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Singh B,
    2. Sundar S
    . 2012. Leishmaniasis: vaccine candidates and perspectives. Vaccine30:3834–3842. doi:10.1016/j.vaccine.2012.03.068.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Bruchhaus I,
    2. Roeder T,
    3. Rennenberg A,
    4. Heussler VT
    . 2007. Protozoan parasites: programmed cell death as a mechanism of parasitism. Trends Parasitol23:376–383. doi:10.1016/j.pt.2007.06.004.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Cabrera-Serra MG,
    2. Lorenzo-Morales J,
    3. Romero M,
    4. Valladares B,
    5. Piñero JE
    . 2007. In vitro activity of perifosine: a novel alkylphospholipid against the promastigote stage of Leishmania species. Parasitol Res100:1155–1157. doi:10.1007/s00436-006-0408-4.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Jain SK,
    2. Sahu R,
    3. Walker LA,
    4. Tekwani BL
    . 2012. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line. J Vis Exp30:pii 4054.
    OpenUrl
  7. 7.↵
    1. Lorenzo-Morales J,
    2. Martín-Navarro CM,
    3. López-Arencibia A,
    4. Santana-Morales MA,
    5. Afonso-Lehmann RN,
    6. Maciver SK,
    7. Valladares B,
    8. Martínez-Carretero E
    . 2010. Therapeutic potential of a combination of two gene-specific small interfering RNAs against clinical strains of Acanthamoeba. Antimicrob Agents Chemother54:5151–5155. doi:10.1128/AAC.00329-10.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Escobar P,
    2. Matu S,
    3. Marques C,
    4. Croft SL
    . 2002. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop81:151–157. doi:10.1016/S0001-706X(01)00197-8.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Glaser J,
    2. Schultheis M,
    3. Hazra S,
    4. Hazra B,
    5. Moll H,
    6. Schurigt U,
    7. Holzgrabe U
    . 2014. Antileishmanial lead structures from nature: analysis of structure-activity relationships of a compound library derived from caffeic acid bornyl ester. Molecules19:1394–1410. doi:10.3390/molecules19021394.
    OpenUrlCrossRef
  10. 10.↵
    1. Sifaoui I,
    2. López-Arencibia A,
    3. Martín-Navarro CM,
    4. Ticona JC,
    5. Reyes-Batlle M,
    6. Mejri M,
    7. Jiménez AI,
    8. Lopez-Bazzocchi I,
    9. Valladares B,
    10. Lorenzo-Morales J,
    11. Abderabba M,
    12. Piñero JE
    . 2014. In vitro effects of triterpenic acids from olive leaf extracts on the mitochondrial membrane potential of promastigote stage of Leishmania spp. Phytomedicine21:1689–1694. doi:10.1016/j.phymed.2014.08.004.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Mukherjee SB,
    2. Das M,
    3. Sudhandiran G,
    4. Shaha C
    . 2002. Increase in cytosolic Ca2+ levels through the activation of non-selective cation channels induced by oxidative stress causes mitochondrial depolarization leading to apoptosis-like death in Leishmania donovani promastigotes. J Biol Chem277:24717–24727. doi:10.1074/jbc.M201961200.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. López-Arencibia A,
    2. García-Velázquez D,
    3. Martín-Navarro CM,
    4. Sifaoui I,
    5. Reyes-Batlle M,
    6. Lorenzo-Morales J,
    7. Gutiérrez-Ravelo Á Piñero JE
    . 2015. In vitro activities of hexaazatrinaphthylenes against Leishmania spp. Antimicrob Agents Chemother59:2867–2874. doi:10.1128/AAC.00226-15.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Kroemer G,
    2. Galluzzi L,
    3. Vandenabeele P,
    4. Abrams J,
    5. Alnemri ES,
    6. Baehrecke EH,
    7. Blagosklonny MV,
    8. El-Deiry WS,
    9. Golstein P,
    10. Green DR,
    11. Hengartner M,
    12. Knight RA,
    13. Kumar S,
    14. Lipton SA,
    15. Malorni W,
    16. Nuñez G,
    17. Peter ME,
    18. Tschopp J,
    19. Yuan J,
    20. Piacentini M,
    21. Zhivotovsky B,
    22. Melino G; Nomenclature Committee on Cell Death
    . 2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ16:3–11. doi:10.1038/cdd.2008.150.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Bou DD,
    2. Tempone AG,
    3. Pinto ÉG,
    4. Lago JH,
    5. Sartorelli P
    . 2014. Antiparasitic activity and effect of casearins isolated from Casearia sylvestris on Leishmania and Trypanosoma cruzi plasma membrane. Phytomedicine21:676–681. doi:10.1016/j.phymed.2014.01.004.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Dorlo TP,
    2. Balasegaram M,
    3. Beijnen JH,
    4. de Vries PJ
    . 2012. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother67:2576–2597. doi:10.1093/jac/dks275.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Fensterle J,
    2. Aicher B,
    3. Seipelt I,
    4. Teifel M,
    5. Engel J
    . 2014. Current view on the mechanism of action of perifosine in cancer. Anticancer Agents Med Chem14:629–635. doi:10.2174/1871520614666140309225912.
    OpenUrlCrossRef
  17. 17.↵
    1. Marinho Fde A,
    2. Gonçalves KC,
    3. Oliveira SS,
    4. Oliveira AC,
    5. Bellio M,
    6. d'Avila-Levy CM,
    7. Santos AL,
    8. Branquinha MH
    . 2011. Miltefosine induces programmed cell death in Leishmania amazonensis promastigotes. Mem Inst Oswaldo Cruz106:507–509. doi:10.1590/S0074-02762011000400021.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Verma NK,
    2. Dey CS
    . 2004. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother48:3010–3015. doi:10.1128/AAC.48.8.3010-3015.2004.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Cabrera-Serra MG,
    2. Valladares B,
    3. Piñero JE
    . 2008. In vivo activity of perifosine against Leishmania amazonensis. Acta Trop108:20–25. doi:10.1016/j.actatropica.2008.08.005.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
Perifosine Mechanisms of Action in Leishmania Species
Atteneri López-Arencibia, Carmen Martín-Navarro, Ines Sifaoui, María Reyes-Batlle, Carolina Wagner, Jacob Lorenzo-Morales, Sutherland K. Maciver, José E. Piñero
Antimicrobial Agents and Chemotherapy Mar 2017, 61 (4) e02127-16; DOI: 10.1128/AAC.02127-16

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Perifosine Mechanisms of Action in Leishmania Species
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Perifosine Mechanisms of Action in Leishmania Species
Atteneri López-Arencibia, Carmen Martín-Navarro, Ines Sifaoui, María Reyes-Batlle, Carolina Wagner, Jacob Lorenzo-Morales, Sutherland K. Maciver, José E. Piñero
Antimicrobial Agents and Chemotherapy Mar 2017, 61 (4) e02127-16; DOI: 10.1128/AAC.02127-16
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Adenosine Triphosphate
Antiprotozoal Agents
Leishmania donovani
Leishmania mexicana
Membrane Potential, Mitochondrial
Phosphorylcholine
perifosine
Leishmania
activity
apoptosis-like

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596